Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Myeloproliferative Neoplasms
•
Hematology
What aspirin dose do you favor for thrombotic prophylaxis in myeloproliferative neoplasms?
81 mg vs 162 mg
Answer from: at Academic Institution
I generally use 81 mg twice a day. If they have had a thrombotic event, or have microvascular symptoms, then I use 81 mg BiD.
Sign in or Register to read more
14664
Related Questions
How do you decide between using ropeginterferon alfa-2b and peginterferon alfa-2a in MPN?
For patients with intermediate or lower risk essential thrombocythemia with plt >1000 but no symptoms, do you favor aspirin only therapy or aspirin and cytoreduction?
Would you change therapy for a CML patient in hematologic remission on imatinib found with positive qualitative BCR-ABL1 for the p230 protein?
What experience have you had with familial clustering of polycythemia vera?
How does triple-negative status influence your management of ET?
For essential thrombocythemia with an indication for aspirin, would you defer therapy if they are on celecoxib?
For patients with essential thrombocythemia already on prophylactic dose DOACs, do you defer starting aspirin?
How would you manage a patient with primary CNS lymphoma who received R-MTX followed by autologous transplant with systemic relapse 5 years later for which R-Pola-CHP was given now followed by CNS relapse?
What whole brain radiation dose would you recommend for primary CNS lymphoma with partial response to HD-MTX-R and R-ICE and planned for concurrent ibrutinib?
What dose and fractionation would you deliver to the sole of the foot in a patient with multifocal cutaneous DLBCL that is resistant to systemic therapy?